Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $34.4167.

A number of equities analysts recently commented on the company. Royal Bank Of Canada raised their target price on Dyne Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, July 30th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday, May 15th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Cantor Fitzgerald started coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They set an “overweight” rating for the company. Finally, TD Cowen initiated coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating for the company.

Insider Buying and Selling

In other news, Director Brian S. Posner bought 2,500 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average price of $17.48 per share, for a total transaction of $43,700.00. Following the purchase, the director owned 22,500 shares in the company, valued at $393,300. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the transaction, the director directly owned 428,946 shares of the company’s stock, valued at $10,723,650. This represents a 83.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 4,139,196 shares of company stock valued at $99,449,852. Company insiders own 9.46% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DYN. Creative Planning boosted its stake in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after buying an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC bought a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $26,000. Caxton Associates LLP lifted its holdings in shares of Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after buying an additional 1,627 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

DYN opened at $25.07 on Friday. Dyne Therapeutics has a 12-month low of $11.92 and a 12-month high of $27.31. The company has a market cap of $4.68 billion, a price-to-earnings ratio of -7.53 and a beta of 1.07. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The company’s 50 day moving average is $24.37 and its 200 day moving average is $20.06.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, equities research analysts predict that Dyne Therapeutics will post -3.47 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.